盐酸埃克替尼治疗EGFR突变型老年非小细胞肺癌的临床疗效与安全性分析
|
摘要
目的探讨盐酸埃克替尼在EGFR突变型老年非小细胞肺癌临床治疗中的的临床疗效及安全性分析。方法选取山东省淄博市张店区人民医院内三科(2015年1月—2017年1月)收治的88例EGFR突变型老年非小细胞肺癌患者分为两组,观察组(n=44)给予盐酸埃克替尼治疗,对照组(n=44)给予吉非替尼治疗,对比两组患者临床疗效和治疗前后炎症因子水平以及不良反应发生率。结果观察组患者的临床缓解几率达到了38.64%,与对照组患者的25.00%相比较差异有统计学意义(χ~2=4.287 9,P<0.05)。治疗后观察组患者IL-2R、IL-6、SAA、CRP水平分别为(454.92±30.83)U/mL、(90.56±14.72)pg/mL、(343.05±8.37)mg/L、(90.46±11.04)mg/L,对照组分别为(634.02±42.15)U/mL、(109.53±14.93)pg/mL、(459.42±8.81)mg/L、(137.04±9.21)mg/L,观察组患者明显低于对照组,差异有统计学意义(t=22.749 4、6.001 7、63.520 9、21.495 3,P<0.05)。观察组的不良反应出现几率为18.18%,显著低于对照组患者的31.82%,差异有统计学意义(χ~2=4.921 3,P<0.05)。结论盐酸埃克替尼能有效降低炎症因子水平,且具有较高的安全性,因此值得临床推广。
Objective To investigate the clinical efficacy and safety of exetinib hydrochloride in the treatment of EGFR mutant elderly non-small cell lung cancer(NSCLC). Methods A total of 88 elderly patients with EGFR mutant nonsmall cell lung cancer admitted to our hospital(from January 2015 to January 2017) were divided into two groups. The observation group(n=44) was treated with ektinib hydrochloride and the control group(n=44) was treated with gefitinib.The clinical efficacy, levels of inflammatory factors and incidence of adverse reactions before and after treatment were compared between the two groups. Results The remission rate of the observation group was 38.64%, which was significantly higher than that of the control group 25.00%(χ~2=4.287 9, P<0.05). After treatment, the levels of IL-2 R, IL-6,SAA and CRP in the observation group were(454.92±30.83)U/mL,(90.56±14.72)pg/mL,(343.05±8.37)mg/L and(90.46±11.04)mg/L, respectively, which were significantly lower than those in the control group(634.02±42.15)U/mL,(109.53±14.93)pg/mL,(459.42±8.81)mg/L,(137.04±9.21)mg/L. The difference was statistically significant(t=22.749 4, 6.001 7,63.520 9, 21.495 3, P<0.05). The incidence of adverse reactions in the two groups was 18.18% vs 31.82%, the difference was significant(χ~2=4.921 3, P<0.05). Conclusion Ectinib hydrochloride can effectively reduce the level of inflammatory factors, and has high safety, so it is worthy of clinical promotion.
Objective To investigate the clinical efficacy and safety of exetinib hydrochloride in the treatment of EGFR mutant elderly non-small cell lung cancer(NSCLC). Methods A total of 88 elderly patients with EGFR mutant nonsmall cell lung cancer admitted to our hospital(from January 2015 to January 2017) were divided into two groups. The observation group(n=44) was treated with ektinib hydrochloride and the control group(n=44) was treated with gefitinib.The clinical efficacy, levels of inflammatory factors and incidence of adverse reactions before and after treatment were compared between the two groups. Results The remission rate of the observation group was 38.64%, which was significantly higher than that of the control group 25.00%(χ~2=4.287 9, P<0.05). After treatment, the levels of IL-2 R, IL-6,SAA and CRP in the observation group were(454.92±30.83)U/mL,(90.56±14.72)pg/mL,(343.05±8.37)mg/L and(90.46±11.04)mg/L, respectively, which were significantly lower than those in the control group(634.02±42.15)U/mL,(109.53±14.93)pg/mL,(459.42±8.81)mg/L,(137.04±9.21)mg/L. The difference was statistically significant(t=22.749 4, 6.001 7,63.520 9, 21.495 3, P<0.05). The incidence of adverse reactions in the two groups was 18.18% vs 31.82%, the difference was significant(χ~2=4.921 3, P<0.05). Conclusion Ectinib hydrochloride can effectively reduce the level of inflammatory factors, and has high safety, so it is worthy of clinical promotion.
引文
[1]李曦,秦娜,王敬慧,等.盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察[J].中国肺癌杂志,2015,18(12):734-739.
[2]张军丽.埃克替尼对EGFR基因突变型非小细胞肺癌患者治疗效果分析[J].安徽医药,2018,22(9):1807-1809.
[3]董娅.埃克替尼治疗中国人群晚期非小细胞肺癌的Meta分析[D].延安:延安大学,2018.
[4]朱永东,解华,舒桂君,等.埃克替尼对表皮生长因子受体突变型晚期非小细胞肺癌的临床疗效观察[J].实用癌症杂志,2017,32(12):1974-1977.
[5]李剑英,许春伟,黄韵坚,等.非小细胞肺癌接受埃克替尼治疗进展后继发性T790M突变[J].临床与病理杂志,2017,37(10):2038-2042.
[6]黄娟.埃克替尼治疗非小细胞肺癌肿瘤体积变化规律及其临床意义的研究[D].青岛:青岛大学,2017.
[7]郭红云,贾亚森,冯国生.埃克替尼联合放疗治疗晚期非小细胞肺癌的研究进展[J].中国临床新医学,2017,10(5):491-494.
[8]游油.埃克替尼一线治疗非小细胞肺癌脑转移的临床观察[D].广州:广州医科大学,2017.
[9]裴斐,贾晓峰,曹永亮.盐酸埃克替尼治疗EGFR突变型老年非小细胞肺癌的临床疗效与安全性分析[J].现代肿瘤医学,2019,5(1):52-55l.
[2]张军丽.埃克替尼对EGFR基因突变型非小细胞肺癌患者治疗效果分析[J].安徽医药,2018,22(9):1807-1809.
[3]董娅.埃克替尼治疗中国人群晚期非小细胞肺癌的Meta分析[D].延安:延安大学,2018.
[4]朱永东,解华,舒桂君,等.埃克替尼对表皮生长因子受体突变型晚期非小细胞肺癌的临床疗效观察[J].实用癌症杂志,2017,32(12):1974-1977.
[5]李剑英,许春伟,黄韵坚,等.非小细胞肺癌接受埃克替尼治疗进展后继发性T790M突变[J].临床与病理杂志,2017,37(10):2038-2042.
[6]黄娟.埃克替尼治疗非小细胞肺癌肿瘤体积变化规律及其临床意义的研究[D].青岛:青岛大学,2017.
[7]郭红云,贾亚森,冯国生.埃克替尼联合放疗治疗晚期非小细胞肺癌的研究进展[J].中国临床新医学,2017,10(5):491-494.
[8]游油.埃克替尼一线治疗非小细胞肺癌脑转移的临床观察[D].广州:广州医科大学,2017.
[9]裴斐,贾晓峰,曹永亮.盐酸埃克替尼治疗EGFR突变型老年非小细胞肺癌的临床疗效与安全性分析[J].现代肿瘤医学,2019,5(1):52-55l.